Autopsy report · NCT00460850

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.

“Low recruitment rate due to treatment regimen change”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 9 months before it stopped.
• 60 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Hoffmann-La Roche

Sponsor type

Industry

Conditions

Hepatitis B, Chronic

Interventions

peginterferon alfa-2a (40KD) [PEGASYS]

Participants

60 (planned, not actual)

Sites

4

Countries

Turkey (Türkiye)

Trials that died the same way

• Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients
  “Low recruitment rate” (80% match in meaning)
• Propofol and Dexmedetomidin vs Midazolam Intraoperative Sedation and POCD
  “Too long recruitment period due to small number of patients” (77% match in meaning)
• Whole-body Vibration Physiotherapy in Kidney Transplantation
  “Due to low recruitment rate” (77% match in meaning)
• NHFOV Versus NCPAP to Prevent Exubation Failure
  “Poor recruitment rate” (76% match in meaning)
• TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors
  “slow recruitment (only 8 patients recruited and treated until 12/2012)” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.